Indo Us Biotech share news, announcements and annual reports
NSE: INDOUSBSE: 541304Agricultural Food & other ProductsSmall Cap
Indo Us Biotech Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2018 on BSE, Sep 2024 on NSE
Last close ₹78.36down ₹8.48 (9.77%)BSE ₹77.78
Share price at the NSE close on 29 Oct 2026. Previous close ₹86.84.
29 Oct: open ₹84.00, high ₹84.00, low ₹76.50
52-week range of traded prices to 28 Oct 2026
₹57.50Low, 26 Oct 2026₹159.00High, 27 Nov 2025
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹174 Cr2,332nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.20
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,44,619
Indo Us Biotech share news and announcements
104 announcements, routine notices left out, newest first. Page 2 of 3.
Nov 2025
Oct 2025
14 Oct · Meeting
1 Oct · Meeting
Sep 2025
30 Sep · Meeting
Aug 2025
28 Aug · Corporate action
28 Aug · Corporate action
28 Aug · Corporate action
28 Aug · Board meeting
13 Aug · Results
12 Aug · Results
12 Aug · Board meeting
4 Aug · Board meeting
Jul 2025
22 Jul · Legal
Significant movement in price has been observed in Indo Us Biotech Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.9 Jul · General Updates
Jun 2025
26 Jun · General Updates
May 2025
26 May · Results
26 May · Results
26 May · Board meeting
17 May · Board meeting
Mar 2025
17 Mar · General Updates
11 Mar · General Updates
7 Mar · Legal
Exchange has sought clarification from Indo Us Biotech Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies -2. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
Feb 2025
11 Feb · Results
11 Feb · Results
11 Feb · Board meeting
3 Feb · Board meeting
Jan 2025
Dec 2024
16 Dec · Meeting
Nov 2024
27 Nov · General Updates
22 Nov · Corrigendum
21 Nov · Corporate action
14 Nov · Results
14 Nov · Meeting
14 Nov · Board meeting
13 Nov · Corporate action